Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice

Vaccine

Volumn 29, Issue 48, 2011, Pages 9081-9092

  Schneider Ohrum, Kirsten ^a,b,c   Giles, Brendan M ^a   Weirback, Heather K ^a   Williams, Brianne L ^a   DeAlmeida, Dilhari R ^a   Ross, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MEDIMMUNE   (United States)

Author keywords

Aged immune system; Influenza; NLR adjuvants; TLR adjuvants; Virus like particles

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; CD11B ANTIGEN; GLYCOPROTEIN P 15095; HEMAGGLUTININ; IMJECT; INFLUENZA VACCINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; SIGNAL TRANSDUCTION; SURVIVAL RATE; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, MUCOSAL; AGE FACTORS; ANIMALS; ANTIBODIES, VIRAL; CARRIER PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TOLL-LIKE RECEPTOR 3; VACCINES, VIRUS-LIKE PARTICLE;

EID: 82455209088     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.051     Document Type: Article

References (61)

1. Lamb, R.A., Krug, R.M., Orthomyxoviridae: the viruses and their replication, in H.P.M. D.M. Knipe, D.E. Griffin, M.A. Malcolm, R.A. Lamb, B. Roizman (Eds.), Fields Virology, Lippincott Williams and Wilkins, Philadelphia, 2001, p. 435-468.
2. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7(10):658-666.
3. Simonsen L., Clarke M.J., Schonberger L.B., Arden N.H., Cox N.J., Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998, 178(1):53-60.
4. Subbarao K., Luke C. H5N1 viruses and vaccines. PLoS Pathog 2007, 3(3):e40.
5. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997, 159:105-117.
6. Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997, 159:95-103.
7. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990, 8:737-771.
8. Kovaiou R.D., Herndler-Brandstetter D., Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007, 9(3):1-17.
9. Aw D., Silva A.B., Palmer D.B. Immunosenescence: emerging challenges for an ageing population. Immunology 2007, 120(4):435-446.
10. Aspinall R., Del Giudice G., Effros R.B., Grubeck-Loebenstein B., Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007, 4:9.
11. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169.
12. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22(3):411-416.
13. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant -- 'the long and winding road'. Drug Discov Today 2009, 14(11-12):541-551.
14. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(4):287-293.
15. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501.
16. Toapanta F.R., Ross T.M. Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res 2009, 10:112.
17. Gillim-Ross L., Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 2006, 19(4):614-636.
18. Chen W., Bennink J.R., Morton P.A., Yewdell J.W. Mice deficient in perforin: CD4+ T cells, or CD28-mediated signaling maintain the typical immunodominance hierarchies of CD8+ T-cell responses to influenza virus. J Virol 2002, 76(20):10332-10337.
19. Clements C.J., Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002, 20(Suppl 3):S24-S33.
20. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live: attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181(3):1133-1137.
21. Chen G.L., Lamirande E.W., Jin H., Kemble G., Subbarao K. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. Virology 2010, 398(1):109-114.
22. McElhaney J.E. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging health 2008, 4(6):603-613.
23. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272(21):1661-1665.
24. Sambhara S., McElhaney J.E. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 2009, 333:413-429.
25. Ehrhardt C., Seyer R., Hrincius E.R., Eierhoff T., Wolff T., Ludwig S. Interplay between influenza A virus and the innate immune signaling. Microbes Infect 2010, 12(1):81-87.
26. Jewell N.A., Vaghefi N., Mertz S.E., Akter P., Peebles R.S., Bakaletz L.O., et al. Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo. J Virol 2007, 81(18):9790-9800.
27. Stout-Delgado H.W., Yang X., Walker W.E., Tesar B.M., Goldstein D.R. Aging impairs IFN regulatory factor 7 up-regulation in plasmacytoid dendritic cells during TLR9 activation. J Immunol 2008, 181:6747-7566.
28. Taylor D.N., Treanor J.J., Strout C., Johnson C., Fitzgerald T., Kavita U., et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011, 29(31):4897-4902.
29. Panda A., Qian F., Mohanty S., van Duin D., Newman F.K., Zhang L., et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010, 184(5):2518-2527.
30. Franceschi C., Monti D., Sansoni P., Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995, 16(1):12-16.
31. Paganelli R., Quinti I., Fagiolo U., Cossarizza A., Ortolani C., Guerra E., et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 1992, 90(2):351-354.
32. Penn N.D., Purkins L., Kelleher J., Heatley R.V., Mascie-Taylor B.H. Ageing and duodenal mucosal immunity. Age Ageing 1991, 20(1):33-36.
33. Snoeck V., Peters I.R., Cox E. The IgA system: a comparison of structure and function in different species. Vet Res 2006, 37(3):455-467.
34. Otten M.A., van Egmond M. The Fc receptor for IgA (FcalphaRI, CD89). Immunol Lett 2004, 92:23-31.
35. Frasca D., Blomberg B.B. Effects of aging on B cell function. Curr Opin Immunol 2009, 21(4):425-430.
36. Frasca D., Diaz A., Romero M., Landin A.M., Phillips M., Lechner S.C., et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 2010, 28(51):8077-8084.
37. Miao H., Hollenbaugh J.A., Zand M.S., Holden-Wiltse J., Mosmann T.R., Perelson A.S., et al. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 2010, 84(13):6687-6698.
38. Po J.L., Gardner E.M., Anaraki F., Katsikis P.D., Murasko D.M. Age-associated decrease in virus-specific CD8+ T lymphocytes during primary influenza infection. Mech Ageing Dev 2002, 123(8):1167-1181.
39. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357(14):1373-1381.
40. Vu T., Farish S., Jenkins M., Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002, 20(13-14):1831-1836.
41. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
42. Ross T.M., Mahmood K., Crevar C.J., Schneider-Ohrum K., Heaton P.M., Bright R.A. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 2009, 4(6):e6032.
43. Durando P., Icardi G., Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010, 10(4):639-651.
44. Wen Z., Ye L., Gao Y., Pan L., Dong K., Bu Z., et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 2009, 84(3):215-224.
45. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep. 59(16): 485-6.
46. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-1351.
47. Lau Y.F., Tang L.H., McCall A.W., Ooi E.E., Subbarao K. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol 2010, 84(17):8639-8649.
48. Katz J.M., Lu X., Todd C.W., Newman M.J. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine 2000, 18(21):2177-2187.
49. Effros R.B., Dagarag M., Spaulding C., Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev 2005, 205:147-157.
50. Haynes L., Eaton S.M. The effect of age on the cognate function of CD4+ T cells. Immunol Rev 2005, 205:220-228.
51. Lavelle E.C. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 2005, 62(23):2750-2770.
52. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75(11):5141-5150.
53. Asahi-Ozaki Y., Itamura S., Ichinohe T., Strong P., Tamura S., Takahashi H., et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 2006, 8(12-13):2706-2714.
54. Kawai T., Akira S. TLR signaling. Cell Death Differ 2006, 13(5):816-825.
55. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008, 60(7):805-812.
56. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433(7028):887-892.
57. Ma D.Y., Clark E.A. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009, 21(5):265-272.
58. Plowden J., Renshaw-Hoelscher M., Gangappa S., Engleman C., Katz J.M., Sambhara S. Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cell Immunol 2004, 229(2):86-92.
59. Sambhara S., Kurichh A., Miranda R., James O., Underdown B., Klein M., et al. Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses. Cell Immunol 2001, 210(1):1-4.
60. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26(42):5393-5399.
61. Lau Y.F., Tang L.H., Ooi E.E., Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 2010, 406(1):80-87.